The Venture Codex Logo

The Venture Codex

Shinhan Venture Investment

18F Glass Tower Bldg 534 Teheran-ro Gangnam-gu, Seoul, 06181, South Korea

Overview

Shinhan Venture Investment operates as an investment company. Shinhan Venture Investment focuses on earlier-stage venture capital investments and later-stage control investments opportunities derived from the latest megatrends such as the aging population, disruptive technologies, IT convergence, alternative energy and etc.

Total investments
33
Lead investments
5
Investments · 12mo
9
Active investors
1

Sector focus

  • Business Development
  • Financial Services
  • Information Technology
  • Venture Capital
Visit website

Investment portfolio

  • Linq

    Participated · Series A · Jul 2026

    LinqAlpha builds a platform that lets institutional investors deploy specialized AI agents that synthesize thousands of signals and learn each user's unique investment framework to surface differentiated insights. The company was founded by Jacob Choi, Subeen Pang, Jin Kim, and Hojun Choi and brings together former Goldman Sachs analysts and MIT computer science PhDs. Since launch, LinqAlpha has been adopted by over 70 financial institutions across the U.S., Europe, and Asia, including sell-side teams at investment banks and buy-side clients such as Causeway Capital Management and Schonfeld Strategic Advisors. Collectively, its buy-side clients manage more than $5 trillion in assets. LinqAlpha is headquartered in New York and plans to use its Series A proceeds to expand its global team, deepen dataset integrations, and accelerate deployment across equities, macro, credit, and multi-asset strategies. The company frames its product as an "Alpha Intelligence Layer" designed to help institutional teams synthesize fast, interconnected public-market signals into actionable judgment.

  • Nventric

    Participated · Equity · Jun 2026

    Enventric develops vascular medical devices for cerebral infarction treatment, with approved products including the EvoGlide distal access catheter and the ULTRIVA stent retriever. The company reported cumulative revenue of about 6 billion won over the past four years and a compound annual growth rate of 52.9% over that period. Enventric is accelerating R&D and expanding manufacturing capacity following recent regulatory approvals. It is pursuing global market entry and has begun formal IPO preparations on KOSDAQ, appointing Kiwoom Securities as its underwriter. The recent 34.5 billion won pre-IPO equity raise broadens its institutional investor base and includes follow-on participation from several existing investors. Management has stated the capital will be used to bolster R&D, scale manufacturing, and support the company’s listing and international expansion efforts.

  • Tokenz

    Participated · Series A · Jun 2026

    Tokenz provides a one-stop MoR platform for digital content providers—game companies, video streaming, manga, and app publishers—handling payments, VAT/GST compliance, invoicing, billing, and customer support. The platform supports over 200 payment methods and offers multi‑language support and country-specific tax processing. Tokenz has secured early commercial adoption with customers including Bushiroad’s HUNTER×HUNTER NEN×SURVIVOR and WonderPlanet’s Crash Fever, and has an alliance to power app‑external payments for Game8 Store. Since beginning service in the latter half of 2024, the company plans to deepen product capabilities such as AI-driven fraud detection and tax optimization, expand its global support footprint, and scale hiring in the payments and FinTech domain. Tokenz was founded in March 2024 and is headquartered in Chiyoda, Tokyo, with Lin Po-Huan as CEO.

  • Subtle Medical

    Participated · Series C · Jun 2026

    Subtle Medical builds vendor-neutral, AI-powered imaging software designed to operate across existing MRI, PET and CT scanners regardless of manufacturer. Its portfolio includes 11 FDA-cleared software products and its technology is deployed on more than 1,300 scanners globally. The company is developing an AI Imaging Hub intended to help providers manage imaging performance across modalities and scanner fleets. Subtle Medical has been recognized by TIME and by CB Insights on multiple industry lists. Financially, the company has raised a total of $86 million following a $33 million growth financing led by Morgan Stanley Expansion Capital. The company plans to use the new capital to accelerate product development and commercial expansion in the U.S. and international markets.

  • Dnotitia

    Participated · Series A · Apr 2026

    Dnotitia develops an AI storage stack centered on Seahorse, a vector database, and VDPU, a dedicated vector data processing semiconductor. In March the company unveiled an AI Storage Strategy to integrate external knowledge, long-term memory, and working memory. Seahorse received Korea’s top-grade GS software certification in January and Seahorse Cloud was launched as a SaaS offering in March. Dnotitia describes VDPU as a purpose-built chip for accelerating vector data search and processing and is preparing it for commercialization. The company plans to use its recent Series A proceeds to improve cloud and on‑premises products, commercialize VDPU, expand globally, and hire key talent. Dnotitia is also moving forward with IPO preparations, naming Korea Investment & Securities and Shinhan Securities as joint lead managers.

Team

  • Ho Jun Lee

    Managing Director & GM